Immunovant (NASDAQ:IMVT) Director Andrew Fromkin Sells 221,951 Shares of Stock

Posted by Geri Gentry on May 30th, 2026

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) Director Andrew Fromkin sold 221,951 shares of Immunovant stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $33.51, for a total transaction of $7,437,578.01. Following the completion of the sale, the director owned 74,382 shares of the company’s stock, valued at $2,492,540.82. This represents a 74.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunovant Stock Down 0.6%

NASDAQ IMVT opened at $33.30 on Friday. Immunovant, Inc. has a 52 week low of $14.09 and a 52 week high of $36.28. The firm has a market capitalization of $6.84 billion, a P/E ratio of -11.98 and a beta of 0.70. The company has a 50-day moving average price of $27.72 and a 200-day moving average price of $26.25.

Immunovant (NASDAQ:IMVT – Get Free Report) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter in the previous year, the firm earned ($0.64) EPS. As a group, equities research analysts anticipate that Immunovant, Inc. will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

IMVT has been the subject of several recent research reports. HC Wainwright boosted their target price on shares of Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Sanford C. Bernstein initiated coverage on shares of Immunovant in a research report on Friday, March 20th. They set a “market perform” rating and a $28.00 target price for the company. Citigroup restated a “buy” rating on shares of Immunovant in a research report on Thursday, May 21st. Bank of America boosted their target price on shares of Immunovant from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Finally, The Goldman Sachs Group boosted their target price on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immunovant has a consensus rating of “Hold” and an average target price of $37.33.

Check Out Our Latest Stock Analysis on IMVT

Hedge Funds Weigh In On Immunovant

A number of hedge funds have recently modified their holdings of IMVT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Immunovant by 8.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after purchasing an additional 3,348 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after purchasing an additional 329,354 shares during the period. Strs Ohio bought a new position in shares of Immunovant in the first quarter worth approximately $27,000. Legal & General Group Plc boosted its position in shares of Immunovant by 6.9% in the second quarter. Legal & General Group Plc now owns 77,296 shares of the company’s stock worth $1,237,000 after purchasing an additional 5,010 shares during the period. Finally, Invesco Ltd. boosted its position in shares of Immunovant by 20.7% in the second quarter. Invesco Ltd. now owns 66,750 shares of the company’s stock worth $1,068,000 after purchasing an additional 11,438 shares during the period. 47.08% of the stock is currently owned by institutional investors.

About Immunovant

(Get Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.